Nobivac DP Plus Evropska unija - slovenščina - EMA (European Medicines Agency)

nobivac dp plus

intervet international b.v. - live attenuated canine distemper virus strain onderstepoort: 105.1 – 106.5 tcid50, live recombinant canine parvovirus strain 630a: 105.1 – 106.7 tcid50 - imunologija za canidae - dogs (small) - for the active immunisation of puppies from 4 weeks of age onwards to prevent clinical signs and mortality of canine distemper virus infection and canine parvovirus infection and to prevent viral excretion following canine distemper virus infection and following canine parvovirus infection.

M-M-RVaxPro Evropska unija - slovenščina - EMA (European Medicines Agency)

m-m-rvaxpro

merck sharp & dohme b.v.  - ošpice virus enders' edmonston sev (v živo, zmanjšan), mumpsu virus jeryl lynn (raven b) sev (v živo, zmanjšan), virus rdečk wistar ra 27/3 sev (v živo, zmanjšan) - rubella; mumps; immunization; measles - cepiva - m-m-rvaxpro je označen za sočasno cepljenje proti ošpicam, mumpsu in rdečkam pri posameznikov 12 mesecev ali več. za uporabo v ošpice izbruhov, ali za post-izpostavljenost cepljenje, ali za uporabo v prej necepljenih otrocih, starejših od 12 mesecev, ki so v stiku z dovzetni nosečnice in osebe verjetno, da je dovzetna za mumpsu in rdečkam.

Qdenga Evropska unija - slovenščina - EMA (European Medicines Agency)

qdenga

takeda gmbh - dengue virus, serotype 2, expressing dengue virus, serotype 1, surface proteins, live, attenuated, dengue virus, serotype 2, expressing dengue virus, serotype 3, surface proteins, live, attenuated, dengue virus, serotype 2, expressing dengue virus, serotype 4, surface proteins, live, attenuated, dengue virus, serotype 2, live, attenuated - dengue - cepiva - qdenga is indicated for the prevention of dengue disease in individuals from 4 years of age. the use of qdenga should be in accordance with official recommendations.

Leucofeligen FeLV/RCP Evropska unija - slovenščina - EMA (European Medicines Agency)

leucofeligen felv/rcp

virbac s.a. - purified p45 feline leukaemia virus envelope antigen, live feline calicivirus (strain f9), live feline viral rhinotracheitis virus (strain f2), live feline panleucopenia virus - v živo mačji panleucopenia virus / parvovirus + live mačji rhinotracheitis virus + live mačji calicivirus + inaktivirano mačji levkemijo virus - mačke - za aktivno imunizacijo mačk, starih osem tednov, proti: mačji kalicivirozi za zmanjšanje kliničnih znakov. mačji virusni rinotraheitis za zmanjšanje kliničnih znakov in virusnega izločanja. mačjo panleukopenijo za preprečevanje levkopenije in zmanjšanje kliničnih znakov. mačje leukemijo za preprečevanje vztrajne viremije in kliničnih znakov s tem povezane bolezni. začetek imunosti: 3 tedne po primarnem cepljenju za komponente panleukopenije in levkemije ter 4 tedne po primarnem cepljenju za komponento virusa kalicivirusa in rinotraheitisa. trajanje imunosti: eno leto po primarnem cepljenju za vse sestavine.

ProQuad Evropska unija - slovenščina - EMA (European Medicines Agency)

proquad

merck sharp & dohme b.v. - virus, živi oslabljeni, ošpice, virus, živi oslabljeni, mumps, virus, živi oslabljeni, rdečkam, virus, živi oslabljen, noric - chickenpox; rubella; measles; mumps; immunization - cepiva - zdravilo proquad je indicirano za sočasno cepljenje proti ošpicam, mumpsu, rdečkam in noricam pri osebah, starih od 12 mesecev. proquad se lahko upravljajo posamezniki iz 9 mesecev starosti v posebnih okoliščinah (e. tako , da so skladni z nacionalnimi cepljenje urnike, izbruh situacijah, ali potovanje v regiji z visoko razširjenost ošpicam.

Pandemic influenza vaccine H5N1 AstraZeneca (previously Pandemic influenza vaccine H5N1 Medimmune) Evropska unija - slovenščina - EMA (European Medicines Agency)

pandemic influenza vaccine h5n1 astrazeneca (previously pandemic influenza vaccine h5n1 medimmune)

astrazeneca ab - reasortantni virus gripe (živi oslabljen) s sevom: a / vietnam / 1203/2004 (h5n1) - gripa, človek - cepiva - preprečevanje gripe pri uradno prijavljeni pandemični situaciji pri otrocih in mladostnikih od 12. meseca do starosti manj kot 18 let. pandemije gripe cepiva proti h5n1 astrazeneca je treba uporabljati v skladu z uradnimi smernice.

Fluenz Tetra Evropska unija - slovenščina - EMA (European Medicines Agency)

fluenz tetra

astrazeneca ab - a/darwin/9/2021 (h3n2) - like strain (a/norway/16606/2021, medi 355293) / a/victoria/2570/2019 (h1n1)pdm09 - like strain (a/victoria/1/2020, medi 340505) / b/austria/1359417/2021 - like strain (b/austria/1359417/2021, medi 355292) / b/phuket/3073/2013 - like strain (b/phuket/3073/2013, medi 306444) - gripa, človek - gripi cepiva, gripi, živo zmanjšan - prophylaxis of influenza in children and adolescents from 24 months to less than 18 years of age. uporaba zdravila fluenz tetra mora temeljiti na uradnih priporočilih.

Purevax RCPCh FeLV Evropska unija - slovenščina - EMA (European Medicines Agency)

purevax rcpch felv

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - immunologicals za skupin felidae, - mačke - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Fluenz Evropska unija - slovenščina - EMA (European Medicines Agency)

fluenz

medimmune llc - reassortant virus influence (v živo zmanjšan) od naslednjih vrst:a/california/7/2009 (h1n1)pdm09 kot seva a/victoria/361/2011 (h3n2), kot sev b/italija/2/2012 kot sev - influenza, human; immunization - cepiva - preprečevanje gripe pri posameznikih od 24 mesecev do manj kot 18 let. uporaba fluenz, ki mora temeljiti na uradnih priporočilih.

Purevax RCPCh Evropska unija - slovenščina - EMA (European Medicines Agency)

purevax rcpch

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - immunologicals za skupin felidae, - mačke - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs. nastopi imunosti so dokazali en teden po primarno cepljenje seveda za rhinotracheitis, calicivirus, chlamydophila felis in panleucopenia komponente. the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.